A Multicenter, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of Saroglitazar in Patients With Primary Biliary Cholangitis

Emerging therapies for PBC

(2020) David Maxwell Hunter Chascsa et al.   JOURNAL OF GASTROENTEROLOGY

Primary Biliary Cholangitis management: controversies, perspectives, and daily practice implications from an expert panel

(2020) Domenico Alvaro et al.   LIVER INTERNATIONAL

Bezafibrate improves GLOBE and UK-PBC scores and long-term outcomes in patients with primary biliary cholangitis

(2019) Akira Honda et al.   HEPATOLOGY

New dual peroxisome proliferator activated receptor agonist—Saroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: integrated analysis of the real world evidence

(2019) Upendra Kaul et al.   Cardiovascular Diabetology

Diagnosis and Management of Primary Biliary Cholangitis

(2018) Zobair M. Younossi et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Long-term clinical impact and cost-effectiveness of obeticholic acid for the treatment of primary biliary cholangitis

(2017) Sumeyye Samur et al.   HEPATOLOGY

EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis

(2017) Gideon M. Hirschfield et al.   JOURNAL OF HEPATOLOGY

Dual PPARα/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models

(2017) Mukul R. Jain et al.   LIVER INTERNATIONAL

Levels of Alkaline Phosphatase and Bilirubin Are Surrogate End Points of Outcomes of Patients With Primary Biliary Cirrhosis: An International Follow-up Study

(2014) Willem J. Lammers et al.   GASTROENTEROLOGY

Pharmacokinetics, Safety, and Tolerability of Saroglitazar (ZYH1), a Predominantly PPARα Agonist with Moderate PPARγ Agonist Activity in Healthy Human Subjects

(2013) Rajendra H. Jani et al.   CLINICAL DRUG INVESTIGATION

Improved Prognosis of Patients With Primary Biliary Cirrhosis That Have a Biochemical Response to Ursodeoxycholic Acid

(2009) Edith M.M. Kuiper et al.   GASTROENTEROLOGY